-E Bajetta Researcher Activity Profile

Research Author Detailed Information 

E Bajetta Publication Rate By Year

E Bajetta has published 1 paper(s) in 1974, 1 paper(s) in 1976, 1 paper(s) in 2001, 10 paper(s) in 2007, for a total of 13 research publications in total.

E E Bajetta Author Information

LAST NAME: bajetta

FIRST NAME: e

INITIALS: E

AFFILIATION:

Papers

E Bajetta's Publication Record

1. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
1Ospedale Niguarda Ca' Granda, Milan, Italy.
2. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
3. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
4. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
5. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
6. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
7. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
8. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
9. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
10. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer] Year Published: 2001
Universitäts-Frauenklinik Klinikum Innenstadt der LMU München, Germany. Harald.Sommer@fk-i.med.uni-muenchen.de
11. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
12. Laparoscopy and laparotomy in staging Hodgkin's and non-Hodgkin's lymphoma. Year Published: 1976
13. Methotrexate (NSC-740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix. Year Published: 1974